Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

[1]  F. Saad,et al.  Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). , 2014 .

[2]  C. Parker,et al.  Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. , 2013, European urology.

[3]  H. Scher,et al.  Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[5]  E. Basch,et al.  Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. , 2012, The Lancet. Oncology.

[6]  Á. Pinto,et al.  Radium-223 Chloride , 2012, Drugs in R&D.

[7]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[8]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[9]  J. Machiels,et al.  Impact of Cabazitaxel (CBZ) + Prednisone (P; CBZP) on Overall Survival (OS) At 2 Yrs and in Patients (PTS) with Aggressive Disease: Post-Hoc Analyses of Tropic Trial , 2012 .

[10]  S. Hitier,et al.  Cabazitaxel (CBZ) + Prednisone (P; CBZP) in Patients (PTS) with Metastatic Castration-Resistant Prostate Cancer (MCRPC) Previously Treated with Docetaxel (D): Interim Results from Compassionate-Use Programme (CUP) and Early-Access Programme (EAP) , 2012 .

[11]  D. Amadori,et al.  Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Bono,et al.  A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy. , 2012 .

[13]  J. Carles,et al.  Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen , 2012 .

[14]  C. Drake,et al.  CA184-043: A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following a single dose of radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D). , 2012 .

[15]  S. Fosså,et al.  Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). , 2012 .

[16]  Sten Nilsson,et al.  Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Fosså,et al.  Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Dreicer.  The future of drug development in urothelial cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. O’Driscoll,et al.  Characterisation and manipulation of docetaxel resistant prostate cancer cell lines , 2011, Molecular Cancer.

[20]  M. Garami,et al.  Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[22]  E. Antonarakis,et al.  Expanding treatment options for metastatic prostate cancer. , 2011, The New England journal of medicine.

[23]  S. Oudard,et al.  A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. DiCenso,et al.  The supportive care needs of men with advanced prostate cancer. , 2011, Oncology nursing forum.

[25]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[26]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[27]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[30]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[31]  B. Sikic,et al.  Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  W T McGivney,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[33]  K. Pienta,et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.

[34]  Thomas Wiegel,et al.  Guidelines on Prostate Cancer , 2013 .

[35]  S. Fosså,et al.  Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[37]  F. Saad,et al.  Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). , 2012, Journal of Clinical Oncology.

[38]  A. Horwich,et al.  Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.